Drug Allergy Pharmacogenetics: A Clinical Perspective

Abstract Purpose of review Genetic variation contributes both to dose-related adverse drug effects and to immune-mediated drug reactions, but these two forms of risk sit in different parts of the genome. We summarize what the practicing allergist and immunologist needs to know about pharmacogenetics, with emphasis on human leukocyte antigen (HLA)-associated delayed reactions, and propose a framework for combining genotype with phenotype, drug chronology and established allergy testing. Recent findings A small number of drug–HLA pairs are clinically actionable, and pre-prescription screening has reduced abacavir hypersensitivity, carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, and allopurinol-induced severe cutaneous adverse reactions in targeted populations. Newer associations show that single-allele screening leaves at-risk patients unidentified and that the dominant risk allele is itself population-dependent. Summary Genotype is best used as a risk modifier and diagnostic adjunct rather than a stand-alone test. Incomplete positive predictive value, residual risk after a negative result, and underrepresentation of geographically heterogeneous populations in discovery cohorts remain the principal barriers to wider implementation.

Authors

Publication Details

Journal
Current Allergy and Asthma Reports
Published
2026-11-12
DOI
https://doi.org/10.1007/s11882-026-01307-z
Primary Topic
Drug-Induced Adverse Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Drug Allergy Pharmacogenetics: A Clinical Perspective

Eric Milan Mukherjee, Matthew Steven Krantz, Elizabeth J. P. Phillips, Rishitha Nalabothu et al.
Current Allergy and Asthma Reports
Drug-Induced Adverse Reactions
article

Drug Allergy Pharmacogenetics: A Clinical Perspective

Eric Milan Mukherjee, Matthew Steven Krantz, Elizabeth J. P. Phillips, Rishitha Nalabothu, Santiago Alvarez Arango
article en

Abstract

Abstract Purpose of review Genetic variation contributes both to dose-related adverse drug effects and to immune-mediated drug reactions, but these two forms of risk sit in different parts of the genome. We summarize what the practicing allergist and immunologist needs to know about pharmacogenetics, with emphasis on human leukocyte antigen (HLA)-associated delayed reactions, and propose a framework for combining genotype with phenotype, drug chronology and established allergy testing. Recent findings A small number of drug–HLA pairs are clinically actionable, and pre-prescription screening has reduced abacavir hypersensitivity, carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, and allopurinol-induced severe cutaneous adverse reactions in targeted populations. Newer associations show that single-allele screening leaves at-risk patients unidentified and that the dominant risk allele is itself population-dependent. Summary Genotype is best used as a risk modifier and diagnostic adjunct rather than a stand-alone test. Incomplete positive predictive value, residual risk after a negative result, and underrepresentation of geographically heterogeneous populations in discovery cohorts remain the principal barriers to wider implementation.

Current Allergy and Asthma ReportsVol. 26(1)
Drug-Induced Adverse Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon